RalA and RalB: Antagonistic Relatives in Cancer Cell Migration
Abstract
The Ral family of small G proteins has been implicated in tumorigenesis, invasion, and metastasis. However, little emphasis has been placed on clarifying the individual roles of the two Ral proteins, RalA and RalB, in these processes in view of their high sequence homology. Here we analyze the separate contributions of RalA and RalB in regulating cell migration, a necessary component of the invasive phenotype, in two human cancer cell lines; UMUC-3, a bladder carcinoma line, and the prostate carcinoma line, DU145. Although inhibiting RalA protein expression by ∼80% with two different small interfering RNA duplexes had no effect on migration, inhibiting RalB expression to the same extent with two different duplexes resulted in a marked reduction in migration. Inhibiting RalB expression did trigger a significant loss of actin cytoskeleton fibers in UMUC-3 that was not seen with inhibition of RalA expression. Interestingly, simultaneous inhibition of RalA and RalB expression had no effect on migration. However, dual inhibition of RalA and RalB expression in UMUC-3 did result in an almost total loss of actin fibers as well as a reduction in proliferation, particularly in reduced serum conditions. These results suggest that RalA and RalB have different roles in cell migration and that they may in fact act as antagonists with regard to this phenotype. As further verification of this hypothesis, we found that expression of constitutively active RalA inhibited migration, whereas expression of constitutively active RalB stimulated migration, consistent with this model. In summary, we present the first demonstration that despite their significant sequence homology, RalA and RalB have nonoverlapping and opposing functions in cancer cell migration but overlapping functions in cell growth.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Active Ral activates cellular processes through effectors including RalBP1, Sec5/Exo85, filamin, and phospholipase D1.
“Active Ral activates cellular processes through effectors including Ral Binding Protein 1 (RalBP1, RLIP76 or RIP17), Sec5/Exo85, filamin, and phospholipase D18–10.”
From Discovery and characterization of small molecules that target the GTPase Ral (2014) · cites this paper as [8]
RBC8 and BQU57 but not RBC5 inhibited both RalA and RalB activation in H2122 and H358 cell lines.
“Additionally, a Ral pull-down assay using RalBP1 agarose beads8 showed that RBC8 and BQU57 but not RBC5 inhibited both RalA and RalB activation in both the H2122 and H358 cell lines (Extended Data Fig. 5e).”
From Discovery and characterization of small molecules that target the GTPase Ral (2014) · cites this paper as [8]
Cited by
Sorted by citations
Discovery and characterization of small molecules that target the GTPase Ral
Yan, C., Liu, D., Li, L., Wempe, M. F., Guin, S., Khanna, M., Meier, J., Hoffman, B., Owens, C., Wysoczynski, C. L., et al. (2014) · Nature · doi:10.1038/nature13713 · Cited by 150 · see citing works
Self-citationCD24 Is an Effector of HIF-1–Driven Primary Tumor Growth and Metastasis
Thomas, S., Harding, M. A., Smith, S. C., Overdevest, J. B., Nitz, M. D., Frierson, H. F., Tomlins, S. A., Kristiansen, G., & Theodorescu, D. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3666 · Cited by 128 · see citing works
Self-citationRal signaling pathway in health and cancer
Moghadam, A. R., Patrad, E., Tafsiri, E., Peng, W., Fangman, B., Pluard, T. J., Accurso, A., Salacz, M., Shah, K., Ricke, B., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1105 · Cited by 58 · see citing works
- Authors
- Oxford, G., Owens, C. R., Titus, B. J., Foreman, T. L., Herlevsen, M. C., Smith, S. C., & Theodorescu, D.
- Affiliations
- University of Virginia (US)
- Venue
- Cancer Research
- Published
- 2005-08-15
- Volume
- 65
- Issue
- 16
- Pages
- 7111-7120
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2066793047
- Cited by
- 139
- References
- 0
- Citations by year
- 2025: 4 · 2024: 1 · 2023: 5 · 2022: 7 · 2021: 10 · 2020: 5 · 2019: 8 · 2018: 3 · 2017: 7 · 2016: 6 · 2015: 10 · 2014: 4 · 2013: 8 · 2012: 10
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 075115)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Keywords
- RalA, RalB, tumor cell migration, actin cytoskeleton, bladder cancer, prostate cancer, metastasis, cell proliferation, siRNA knockdown
- MeSH terms
- Actins, Urinary Bladder Neoplasms, Cell Movement, Humans, Male, Prostatic Neoplasms, ral GTP-Binding Proteins, RNA, Small Interfering, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review